All In Biotech

Drug Trial Radar · NCT03748186

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

136

Actual

Start

Feb 1, 2019

Primary completion

Jun 4, 2024

Study completion Jun 4, 2024

Sponsor

Lead sponsor
Sutro Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Nov 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Conditions

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovary Cancer
  • Endometrial Cancer
  • Endometrioid Adenocarcinoma
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Interventions

  • STRO-002Drug

    intravenous antibody drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)Time frame: 18 months
  2. Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002Time frame: 18 months
  3. Part 1: Define the maximum tolerated dose (MTD) of STRO-002Time frame: 18 months
  4. Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)Time frame: 24 months
  5. Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)Time frame: 24 months

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Oncology - Tucson

    Tucson, Arizona

  • UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit

    Los Angeles, California

  • Sutter Health- Palo Alto Medical Foundation

    San Francisco, California

  • Rocky Mountain Cancer Center

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Miami Cancer Institue, Baptist Health South Florida

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Augusta Oncology

    Augusta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Maryland Oncology Hematology

    Rockville, Maryland

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • NYU Langone Medical Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • Ohio State University, James Cancer Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Prisma Health

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Cancer Care Northwest-South Spokane

    Spokane, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain

  • Clínica Universidad de Navarra -Madrid

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro - CIOCC

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.